HU200931B - Process for producing pharmaceutical nucleozides - Google Patents

Process for producing pharmaceutical nucleozides Download PDF

Info

Publication number: HU200931B
Authority: HU; Hungary
Prior art keywords: formula; purine; active ingredient; compound; dideoxy
Prior art date: 1987-11-07

Application number

HU885714A

Other languages

English (en)

Hungarian (hu)

Other versions

HUT48466A (en

Inventor

Luise Burns Charlene

Mary Daluge Susan

Walter Koszalka George

Anthony Krenitsky Thomas

Tuttle Joel Van

Original Assignee

Wellcome Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-11-07

Filing date

1988-11-04

Publication date

1990-09-28

1988-11-04 Application filed by Wellcome Found filed Critical Wellcome Found

1989-06-28 Publication of HUT48466A publication Critical patent/HUT48466A/hu

1990-09-28 Publication of HU200931B publication Critical patent/HU200931B/hu

Links

238000000034 method Methods 0.000 title claims description 15
150000001875 compounds Chemical class 0.000 claims description 34
229910052739 hydrogen Inorganic materials 0.000 claims description 12
238000002360 preparation method Methods 0.000 claims description 12
239000008194 pharmaceutical composition Substances 0.000 claims description 7
125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
229910052757 nitrogen Inorganic materials 0.000 claims description 5
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 4
-1 cyclopropylamino, methoxy, cyclopentoxy Chemical group 0.000 claims description 4
239000001257 hydrogen Substances 0.000 claims description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 4
125000003545 alkoxy group Chemical group 0.000 claims description 3
125000000000 cycloalkoxy group Chemical group 0.000 claims description 3
125000006310 cycloalkyl amino group Chemical group 0.000 claims description 3
125000000623 heterocyclic group Chemical group 0.000 claims description 3
125000003386 piperidinyl group Chemical group 0.000 claims description 3
238000012546 transfer Methods 0.000 claims description 3
102000004190 Enzymes Human genes 0.000 claims description 2
108090000790 Enzymes Proteins 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
125000001805 pentosyl group Chemical group 0.000 claims description 2
239000007858 starting material Substances 0.000 claims description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
239000003937 drug carrier Substances 0.000 claims 1
150000002148 esters Chemical class 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
241000725303 Human immunodeficiency virus Species 0.000 abstract description 8
230000000840 anti-viral effect Effects 0.000 abstract description 4
230000003389 potentiating effect Effects 0.000 abstract 1
239000002212 purine nucleoside Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 description 45
239000004480 active ingredient Substances 0.000 description 38
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
239000000047 product Substances 0.000 description 23
238000009472 formulation Methods 0.000 description 20
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
229920005989 resin Polymers 0.000 description 17
239000011347 resin Substances 0.000 description 17
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
241000700605 Viruses Species 0.000 description 12
239000000741 silica gel Substances 0.000 description 12
229910002027 silica gel Inorganic materials 0.000 description 12
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 11
239000002904 solvent Substances 0.000 description 11
239000003826 tablet Substances 0.000 description 11
101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 10
102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 10
101710132082 Pyrimidine/purine nucleoside phosphorylase Proteins 0.000 description 10
102000013537 Thymidine Phosphorylase Human genes 0.000 description 10
208000030507 AIDS Diseases 0.000 description 9
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
239000002775 capsule Substances 0.000 description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
239000008101 lactose Substances 0.000 description 8
210000004027 cell Anatomy 0.000 description 7
208000015181 infectious disease Diseases 0.000 description 7
239000004615 ingredient Substances 0.000 description 7
235000019359 magnesium stearate Nutrition 0.000 description 7
239000002777 nucleoside Substances 0.000 description 7
239000000725 suspension Substances 0.000 description 7
238000011282 treatment Methods 0.000 description 7
241001430294 unidentified retrovirus Species 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
239000007788 liquid Substances 0.000 description 6
238000007906 compression Methods 0.000 description 5
230000006835 compression Effects 0.000 description 5
238000000921 elemental analysis Methods 0.000 description 5
TZLVRPLSVNESQC-UHFFFAOYSA-N potassium azide Chemical compound [K+].[N-]=[N+]=[N-] TZLVRPLSVNESQC-UHFFFAOYSA-N 0.000 description 5
239000008057 potassium phosphate buffer Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
206010001513 AIDS related complex Diseases 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
229920001429 chelating resin Polymers 0.000 description 4
229960001760 dimethyl sulfoxide Drugs 0.000 description 4
ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
239000000796 flavoring agent Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
229940069328 povidone Drugs 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
229920003109 sodium starch glycolate Polymers 0.000 description 4
229940079832 sodium starch glycolate Drugs 0.000 description 4
239000008109 sodium starch glycolate Substances 0.000 description 4
239000007787 solid Substances 0.000 description 4
208000031886 HIV Infections Diseases 0.000 description 3
241000598436 Human T-cell lymphotropic virus Species 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000013270 controlled release Methods 0.000 description 3
238000007907 direct compression Methods 0.000 description 3
238000011049 filling Methods 0.000 description 3
235000011187 glycerol Nutrition 0.000 description 3
239000008187 granular material Substances 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000001819 mass spectrum Methods 0.000 description 3
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
230000000750 progressive effect Effects 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
239000002562 thickening agent Substances 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 2
OQRXBXNATIHDQO-UHFFFAOYSA-N 6-chloropyridine-3,4-diamine Chemical compound NC1=CN=C(Cl)C=C1N OQRXBXNATIHDQO-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
241000450599 DNA viruses Species 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
208000037357 HIV infectious disease Diseases 0.000 description 2
206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 2
241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
241000714259 Human T-lymphotropic virus 2 Species 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
208000008771 Lymphadenopathy Diseases 0.000 description 2
102100036286 Purine nucleoside phosphorylase Human genes 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical group [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
239000013543 active substance Substances 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
239000007891 compressed tablet Substances 0.000 description 2
125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 2
125000006317 cyclopropyl amino group Chemical group 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000000155 melt Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 2
125000003835 nucleoside group Chemical group 0.000 description 2
108010009099 nucleoside phosphorylase Proteins 0.000 description 2
239000006072 paste Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000001177 retroviral effect Effects 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
238000007493 shaping process Methods 0.000 description 2
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
235000010234 sodium benzoate Nutrition 0.000 description 2
239000004299 sodium benzoate Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000005550 wet granulation Methods 0.000 description 2
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
XKKCQTLDIPIRQD-JGVFFNPUSA-N 1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)CC1 XKKCQTLDIPIRQD-JGVFFNPUSA-N 0.000 description 1
WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 1
BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 description 1
RYYIULNRIVUMTQ-UHFFFAOYSA-N 6-chloroguanine Chemical compound NC1=NC(Cl)=C2N=CNC2=N1 RYYIULNRIVUMTQ-UHFFFAOYSA-N 0.000 description 1
MPZIWCHLJUGUQQ-UHFFFAOYSA-N 6-cyclopentyloxy-7h-purine Chemical compound C1CCCC1OC1=NC=NC2=C1NC=N2 MPZIWCHLJUGUQQ-UHFFFAOYSA-N 0.000 description 1
OXCZAXJFRBPQRP-UHFFFAOYSA-N 6-piperidin-1-yl-7h-purine Chemical compound C1CCCCN1C1=NC=NC2=C1NC=N2 OXCZAXJFRBPQRP-UHFFFAOYSA-N 0.000 description 1
244000144730 Amygdalus persica Species 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
208000014912 Central Nervous System Infections Diseases 0.000 description 1
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
206010013887 Dysarthria Diseases 0.000 description 1
208000032274 Encephalopathy Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
241000713310 Human T-cell lymphotropic virus type 4 Species 0.000 description 1
241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920003094 Methocel™ K4M Polymers 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
235000006040 Prunus persica var persica Nutrition 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
206010037549 Purpura Diseases 0.000 description 1
241001672981 Purpura Species 0.000 description 1
206010038997 Retroviral infections Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
239000002269 analeptic agent Substances 0.000 description 1
229940089206 anhydrous dextrose Drugs 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000002281 colonystimulating effect Effects 0.000 description 1
208000004209 confusion Diseases 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000003210 demyelinating effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
206010013395 disorientation Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
230000000694 effects Effects 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
229940116364 hard fat Drugs 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
208000003669 immune deficiency disease Diseases 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
208000018555 lymphatic system disease Diseases 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
ZVXQITNIMKKBBE-UHFFFAOYSA-N n-cyclopropyl-7h-purin-6-amine Chemical compound C1CC1NC1=NC=NC2=C1N=CN2 ZVXQITNIMKKBBE-UHFFFAOYSA-N 0.000 description 1
CRIGWITUYGOXOY-UHFFFAOYSA-N n-ethyl-2-[2-(4-fluoroanilino)-2-oxoethyl]-3-oxopiperazine-1-carboxamide Chemical compound CCNC(=O)N1CCNC(=O)C1CC(=O)NC1=CC=C(F)C=C1 CRIGWITUYGOXOY-UHFFFAOYSA-N 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
238000010534 nucleophilic substitution reaction Methods 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
230000001148 spastic effect Effects 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000002731 stomach secretion inhibitor Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000013519 translation Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
229960002555 zidovudine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

HU885714A 1987-11-07 1988-11-04 Process for producing pharmaceutical nucleozides HU200931B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB878726136A GB8726136D0 (en)	1987-11-07	1987-11-07	Therapeutic nucleosides

Publications (2)

Publication Number	Publication Date
HUT48466A HUT48466A (en)	1989-06-28
HU200931B true HU200931B (en)	1990-09-28

Family

ID=10626612

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HU885714A HU200931B (en)	1987-11-07	1988-11-04	Process for producing pharmaceutical nucleozides
HU902123A HU204839B (en)	1987-11-07	1988-11-04	Process for producing pharmaceutical compositions against viruses causing immune deficiency

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HU902123A HU204839B (en)	1987-11-07	1988-11-04	Process for producing pharmaceutical compositions against viruses causing immune deficiency

Country Status (17)

Country	Link
US (1)	US5574149A (de)
EP (3)	EP0669341A1 (de)
JP (1)	JP2731551B2 (de)
KR (1)	KR890008160A (de)
AT (1)	ATE131826T1 (de)
AU (1)	AU616914B2 (de)
CA (1)	CA1333391C (de)
DE (1)	DE3854811T2 (de)
DK (1)	DK615788A (de)
ES (1)	ES2081286T3 (de)
FI (1)	FI91763C (de)
GB (1)	GB8726136D0 (de)
GR (1)	GR3019379T3 (de)
HU (2)	HU200931B (de)
MX (1)	MX9203217A (de)
PT (1)	PT88948B (de)
ZA (1)	ZA888289B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5506215A (en) *	1987-11-03	1996-04-09	Medivir Ab	1-(3'-fluoro-2',3'-dideoxy-β-D-ribofuranosyl)-5-substituted pyrimidine nucleosides
US5157114A (en) *	1988-08-19	1992-10-20	Burroughs Wellcome Co.	2',3'-dideoxy-3'-fluoro-5-ethyngluridine
WO1990003978A1 (en) *	1988-10-03	1990-04-19	Stichting Rega Vzw	5-halogeno-3'-fluoro-2',3'-dideoxyuridine compounds and their therapeutic application
CA2073063A1 (en) *	1989-11-06	1991-05-07	Jo Klaveness	Nucleoside derivatives
FR2668153B1 (fr) *	1990-10-22	1995-03-31	Pasteur Merieux Serums Vacc	Nouveaux composes ribonucleosides, leur procede de preparation et les medicaments les contenant.
GB9200150D0 (en) *	1992-01-06	1992-02-26	Wellcome Found	Therapeutic nucleosides
DE69324244T2 (de) *	1992-01-06	1999-09-30	The Wellcome Foundation Ltd., Greenford	Therapeutische nukleoside der 2',3'-dideoxy-3'-fluor -purin reihe
HU9501978D0 (en) *	1993-03-31	1995-09-28	Sterling Winthorp Inc	Bifunctional nucleosides, oligomers thereof, and methods of making and using the same
ES2121204T3 (es) *	1993-05-12	1998-11-16	Rhodia Limited	Preparacion de fluoro-nucleosidos e intermedios para su uso en ella.
PT917879E (pt) *	1997-11-22	2002-12-31	Roche Diagnostics Gmbh	Processo melhorado para estabilizacao de proteinas
US6156349A (en) *	1998-12-14	2000-12-05	Steinbach, Pylant And Herman, L.L.C.	Method of treating HIV infection with suppository containing mammalian liver extract
US6514979B1 (en)	1999-03-03	2003-02-04	University Of Maryland Biotechnology Institute	Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
EP1478322A4 (de) *	2001-06-22	2007-08-08	Pharmasset Ltd	Beta-2'-OR 3'-HALONUCLEOSIDE

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3328388A (en) *	1964-09-02	1967-06-27	Merck & Co Inc	Arabinofuranosyl pyrimidines and methods of preparing same
US3775397A (en) *	1969-11-12	1973-11-27	Akad Wissenschaften Ddr	Novel cytostatic 2',3'-dideoxy-3'-fluoropyrimidine-nucleosides
SE8602981D0 (sv) *	1986-07-04	1986-07-04	Astra Laekemedel Ab	Novel medicinal use
US5153180A (en) *	1986-07-24	1992-10-06	Eckart Matthes	Fluorinated nucleosides and process for treating retrovirus infections therewith
DD279407A1 (de) *	1986-07-24	1990-06-06	Akad Wissenschaften Ddr	Verfahren zur herstellung eines mittels gegen aids
GB8719877D0 (en) *	1987-08-22	1987-09-30	Wellcome Found	Antiviral compounds
SE8704298D0 (sv) *	1987-11-03	1987-11-03	Astra Ab	Compounds for use in therapy

1987
- 1987-11-07 GB GB878726136A patent/GB8726136D0/en active Pending
1988
- 1988-11-03 AT AT88310344T patent/ATE131826T1/de not_active IP Right Cessation
- 1988-11-03 ES ES88310344T patent/ES2081286T3/es not_active Expired - Lifetime
- 1988-11-03 EP EP95108713A patent/EP0669341A1/de not_active Withdrawn
- 1988-11-03 DE DE3854811T patent/DE3854811T2/de not_active Expired - Fee Related
- 1988-11-03 EP EP95108714A patent/EP0670328A1/de not_active Withdrawn
- 1988-11-03 EP EP88310344A patent/EP0317128B1/de not_active Expired - Lifetime
- 1988-11-04 ZA ZA888289A patent/ZA888289B/xx unknown
- 1988-11-04 PT PT88948A patent/PT88948B/pt not_active IP Right Cessation
- 1988-11-04 HU HU885714A patent/HU200931B/hu not_active IP Right Cessation
- 1988-11-04 JP JP63279196A patent/JP2731551B2/ja not_active Expired - Lifetime
- 1988-11-04 DK DK615788A patent/DK615788A/da not_active Application Discontinuation
- 1988-11-04 FI FI885094A patent/FI91763C/fi not_active IP Right Cessation
- 1988-11-04 HU HU902123A patent/HU204839B/hu not_active IP Right Cessation
- 1988-11-04 CA CA000582322A patent/CA1333391C/en not_active Expired - Fee Related
- 1988-11-04 AU AU24763/88A patent/AU616914B2/en not_active Ceased
- 1988-11-04 KR KR1019880014472A patent/KR890008160A/ko not_active Ceased
1992
- 1992-06-24 MX MX9203217A patent/MX9203217A/es unknown
1993
- 1993-05-17 US US08/062,591 patent/US5574149A/en not_active Expired - Fee Related
1996
- 1996-03-20 GR GR960400779T patent/GR3019379T3/el unknown

Also Published As

Publication number	Publication date
AU616914B2 (en)	1991-11-14
GR3019379T3 (en)	1996-06-30
JP2731551B2 (ja)	1998-03-25
DE3854811T2 (de)	1996-08-01
DK615788D0 (da)	1988-11-04
DK615788A (da)	1989-05-08
FI885094A0 (fi)	1988-11-04
EP0669341A1 (de)	1995-08-30
EP0317128A2 (de)	1989-05-24
AU2476388A (en)	1989-05-25
EP0317128B1 (de)	1995-12-20
PT88948B (pt)	1993-02-26
ATE131826T1 (de)	1996-01-15
CA1333391C (en)	1994-12-06
PT88948A (pt)	1988-12-01
FI885094A7 (fi)	1989-05-08
HU204839B (en)	1992-02-28
EP0317128A3 (de)	1991-10-02
HU902123D0 (en)	1990-07-28
FI91763C (fi)	1994-08-10
HUT48466A (en)	1989-06-28
JPH01153697A (ja)	1989-06-15
KR890008160A (ko)	1989-07-10
ZA888289B (en)	1990-07-25
EP0670328A1 (de)	1995-09-06
ES2081286T3 (es)	1996-03-01
DE3854811D1 (de)	1996-02-01
US5574149A (en)	1996-11-12
MX9203217A (es)	1992-07-01
FI91763B (fi)	1994-04-29
GB8726136D0 (en)	1987-12-09

Legal Events

Date	Code	Title
1992-08-28	HMM4	Cancellation of final prot. due to non-payment of fee
1992-11-30	HRH9	Withdrawal of annulment decision
1997-09-29	HMM4	Cancellation of final prot. due to non-payment of fee

Publication	Publication Date	Title
CA1314875C (en)	1993-03-23	Therapeutic nucleosides
EP0286425B1 (de)	1995-01-11	Therapeutische Nukleoside
JPS61257926A (ja)	1986-11-15	治療用ヌクレオシド
WO1996013512A2 (en)	1996-05-09	L-ribofuranosyl nucleosides
JPH08501071A (ja)	1996-02-06	１，５−アンヒドロヘキシトールヌクレオシド類似体および該類似体の医薬としての使用
MXPA97002932A (en)	1998-04-01	L-ribofuranosilnucleosi
HU200931B (en)	1990-09-28	Process for producing pharmaceutical nucleozides
EP0285432B1 (de)	1992-11-11	Therapeutische Nukleoside
US5071983A (en)	1991-12-10	Therapeutic nucleosides
TW205044B (de)	1993-05-01
JPS6310787A (ja)	1988-01-18	ヌクレオシド類縁体、その製造法および抗ウイルス剤
US4920210A (en)	1990-04-24	2,6-diaminopurine-9-β-D-2',3'-dideoxyribofuranoside
JPH07502740A (ja)	1995-03-23	治療用ヌクレオシド
HU201953B (en)	1991-01-28	Process for producing new nucleoside derivatives and pharmaceutical compositions comprising same as active ingredient
WO1988009332A1 (en)	1988-12-01	Therapeutic nucleosides
US5175274A (en)	1992-12-29	Therapeutic nucleosides
EP0617046A1 (de)	1994-09-28	Nucleosidderivate und Antiherpes-Zusammensetzung
CA1336821C (en)	1995-08-29	Therapeutic nucleosides
CA2203672A1 (en)	1996-05-09	L-ribofuranosyl nucleosides
EP0294113A1 (de)	1988-12-07	Therapeutische Nucleoside